The global market for Neurodegenerative Diseases Therapeutics was valued at US$50.4 Billion in 2024 and is projected to reach US$71.7 Billion by 2030, growing at a CAGR of 6.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Over the past decade, the field of neurodegenerative disease therapeutics has witnessed remarkable advancements, propelled by a deeper understanding of disease mechanisms and technological innovations. Traditional pharmacological treatments have been supplemented by novel approaches targeting the underlying pathology of these diseases. For instance, monoclonal antibodies designed to clear amyloid-beta plaques have shown promise in Alzheimer's disease, while gene therapies are being explored for their potential to correct genetic mutations in conditions like Huntington's disease. Additionally, the use of biomarkers for early diagnosis and personalized medicine approaches are becoming increasingly prevalent, allowing for more tailored and effective treatment strategies. Clinical trials and research efforts continue to expand, providing a pipeline of potential new therapies that could transform the management of neurodegenerative diseases.
The growth in the neurodegenerative diseases therapeutics market is driven by several factors, including technological advancements, increasing prevalence of neurodegenerative disorders, and heightened investment in research and development. Innovations in biotechnology and molecular biology have paved the way for cutting-edge treatments such as CRISPR-based gene editing and stem cell therapies, which hold the promise of addressing the root causes of these diseases. The aging global population is contributing to a higher incidence of neurodegenerative conditions, thereby increasing the demand for effective treatments. Furthermore, substantial investments from pharmaceutical companies and government agencies are fueling the development of new therapeutics. Collaborative efforts between academia, industry, and regulatory bodies are accelerating the pace of discovery and approval of new treatments. These factors, combined with a growing understanding of disease mechanisms and the advent of precision medicine, are driving the robust expansion of the neurodegenerative diseases therapeutics market, offering hope for improved outcomes for patients worldwide.
Global Neurodegenerative Diseases Therapeutics Market - Key Drivers and Trends Summarized
Neurodegenerative diseases therapeutics encompass a broad array of treatments aimed at managing and potentially altering the course of diseases characterized by progressive nervous system dysfunction. These diseases include Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis (ALS), among others. The primary focus of these therapeutics is to alleviate symptoms, improve quality of life, and, in some cases, slow disease progression. Treatments range from pharmacological interventions, such as cholinesterase inhibitors and dopamine agonists, to advanced approaches like gene therapy and neuroprotective agents.Over the past decade, the field of neurodegenerative disease therapeutics has witnessed remarkable advancements, propelled by a deeper understanding of disease mechanisms and technological innovations. Traditional pharmacological treatments have been supplemented by novel approaches targeting the underlying pathology of these diseases. For instance, monoclonal antibodies designed to clear amyloid-beta plaques have shown promise in Alzheimer's disease, while gene therapies are being explored for their potential to correct genetic mutations in conditions like Huntington's disease. Additionally, the use of biomarkers for early diagnosis and personalized medicine approaches are becoming increasingly prevalent, allowing for more tailored and effective treatment strategies. Clinical trials and research efforts continue to expand, providing a pipeline of potential new therapies that could transform the management of neurodegenerative diseases.
The growth in the neurodegenerative diseases therapeutics market is driven by several factors, including technological advancements, increasing prevalence of neurodegenerative disorders, and heightened investment in research and development. Innovations in biotechnology and molecular biology have paved the way for cutting-edge treatments such as CRISPR-based gene editing and stem cell therapies, which hold the promise of addressing the root causes of these diseases. The aging global population is contributing to a higher incidence of neurodegenerative conditions, thereby increasing the demand for effective treatments. Furthermore, substantial investments from pharmaceutical companies and government agencies are fueling the development of new therapeutics. Collaborative efforts between academia, industry, and regulatory bodies are accelerating the pace of discovery and approval of new treatments. These factors, combined with a growing understanding of disease mechanisms and the advent of precision medicine, are driving the robust expansion of the neurodegenerative diseases therapeutics market, offering hope for improved outcomes for patients worldwide.
Report Scope
The report analyzes the Neurodegenerative Diseases Therapeutics market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments
Drug Class (Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors, Other Drug Classes); Disease Type (Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease, Other Disease Types); Distribution Channel (Drug Store & Retail Pharmacies, Hospital Pharmacies, Online Pharmacies).Geographic Regions/Countries
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Immunomodulators segment, which is expected to reach US$30 Billion by 2030 with a CAGR of a 6.6%. The Dopamine Agonists segment is also set to grow at 5.4% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $13.6 Billion in 2024, and China, forecasted to grow at an impressive 9.8% CAGR to reach $15.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AbbVie, Inc., Alector, Inc., AstraZeneca PLC, Biohaven, Ltd., Bristol-Myers Squibb Company and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Neurodegenerative Diseases Therapeutics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Neurodegenerative Diseases Therapeutics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Neurodegenerative Diseases Therapeutics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 45 major companies featured in this Neurodegenerative Diseases Therapeutics market report include:
- AbbVie, Inc.
- Alector, Inc.
- AstraZeneca PLC
- Biohaven, Ltd.
- Bristol-Myers Squibb Company
- Coya Therapeutics
- Denali Therapeutics, Inc.
- Eli Lilly and Company
- Genentech, Inc.
- H. Lundbeck A/S
- Ionis Pharmaceuticals, Inc.
- Les Laboratoires Servier
- MD Biosciences, Inc.
- Ono Pharmaceutical Co., Ltd.
- Prothena Corporation PLC
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie, Inc.
- Alector, Inc.
- AstraZeneca PLC
- Biohaven, Ltd.
- Bristol-Myers Squibb Company
- Coya Therapeutics
- Denali Therapeutics, Inc.
- Eli Lilly and Company
- Genentech, Inc.
- H. Lundbeck A/S
- Ionis Pharmaceuticals, Inc.
- Les Laboratoires Servier
- MD Biosciences, Inc.
- Ono Pharmaceutical Co., Ltd.
- Prothena Corporation PLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 387 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 50.4 Billion |
| Forecasted Market Value ( USD | $ 71.7 Billion |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | Global |
